DNA vaccination against bcr-abl-positive cells in mice

被引:12
|
作者
Lucansky, Vincent [1 ]
Sobotkova, Eva [1 ]
Tachezy, Ruth [1 ]
Duskova, Martina [1 ]
Vonka, Vladimir [1 ]
机构
[1] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague 2, Czech Republic
关键词
CML; bcr-abl-transformed mouse cells; DNA vaccines; CHRONIC MYELOGENOUS LEUKEMIA; LOADED DENDRITIC CELLS; IMATINIB MESYLATE; FUSION PEPTIDES; IMMUNOTHERAPY; ONCOGENE; IMMUNOGENICITY; TRANSFORMATION; MECHANISMS; DISEASE;
D O I
10.3892/ijo_00000408
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A series of DNA vaccines based on the bcr-abl fusion gene were developed and tested in mice. Two mouse (BALB/c) bcr-abl-transformed cell lines, B210 and 12131, which both expressed p210(bcr-abl) and were oncogenic for syngeneic animals but differed in some other respects, were used as a model system. In the first series of experiments, plasmids carrying either the complete bcr-abl fusion gene or a fragment thereof coding for a 25-amino acid-long junction zone (bcr-abl25aa) linked with genes coding for a variety of immunostimulatory factors were used as the DNA vaccines. A plasmid carrying the complete bcr-abl gene was capable of inducing protection against challenge with either B210 or 12B1 cells. However, the DNA vaccines based on the gene fragment coding for p25aa(bcr-abl) did not induce significant protection. To localize the immunizing epitopes on the p210(bcr-abl) protein, the whole fusion gene was split into nine overlapping fragments and these, individually or in various combinations, were used for immunization. Although none of the vaccines based on any single fragment provided potent protection, some combinations of these fragment-based vaccines were capable of eliciting protection comparable to that seen after immunization with the whole-gene vaccine. Surprisingly, a mixture of six fragment-vaccines was more immunogenic than the complete set of fragment DNA vaccines. To analyze this phenomenon, the three fragments missing from the hexavaccine were either individually or in various combinations mixed with the hexavaccine. The results obtained suggested that the product of the fragment coding for 197 amino acids forming the N-terminal of the BCR protein was involved in the decreased immunogenicity. However, further experiments are needed to clarify the point. Additional experiments revealed that all the important epitopes were located in the ABL portion of the p210(bcr-abl) protein. The livers, spleens and bone marrows of the successfully immunized animals were tested for the presence of bcr-abl-positive cells by RT-PCR. The results were negative, this suggesting that these animals were free of any residual disease.
引用
收藏
页码:941 / 951
页数:11
相关论文
共 50 条
  • [1] Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia
    Makiko Morita
    Yoko Nishinaka
    Itaru Kato
    Satoshi Saida
    Hidefumi Hiramatsu
    Yasuhiko Kamikubo
    Toshio Heike
    Tatsutoshi Nakahata
    Souichi Adachi
    International Journal of Hematology, 2017, 105 : 335 - 340
  • [2] Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia
    Morita, Makiko
    Nishinaka, Yoko
    Kato, Itaru
    Saida, Satoshi
    Hiramatsu, Hidefumi
    Kamikubo, Yasuhiko
    Heike, Toshio
    Nakahata, Tatsutoshi
    Adachi, Souichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 335 - 340
  • [3] Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Tanaka, Yuko
    Katagiri, Seiichiro
    Kitahara, Toshihiko
    Ohyashiki, Kazuma
    BLOOD, 2013, 122 (17) : 3086 - 3088
  • [4] Grb10 is involved in BCR-ABL-positive leukemia in mice
    A L Illert
    C Albers
    S Kreutmair
    H Leischner
    C Peschel
    C Miething
    J Duyster
    Leukemia, 2015, 29 : 858 - 868
  • [5] ANTILEUKEMIC EFFECT OF PLK INHIBITOR AND IN COMBINATION WITH ABL TYROSINE KINASE INHIBITORS AGAINST BCR-ABL-POSITIVE CELLS
    Okabe, S.
    Tauchi, T.
    Tanaka, Y.
    Kitahara, T.
    Ohyashiki, K.
    HAEMATOLOGICA, 2014, 99 : 70 - 70
  • [6] Grb10 is involved in BCR-ABL-positive leukemia in mice
    Illert, A. L.
    Albers, C.
    Kreutmair, S.
    Leischner, H.
    Peschel, C.
    Miething, C.
    Duyster, J.
    LEUKEMIA, 2015, 29 (04) : 858 - 868
  • [7] Management of Bcr-Abl-positive leukemias with dasatinib
    Hochhaus, Andreas
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (11) : 1529 - 1536
  • [8] Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice
    He, L
    Feng, HP
    Raymond, A
    Kreeger, M
    Zeng, Y
    Graner, M
    Whitesell, L
    Katsanis, E
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2001, 50 (01) : 31 - 40
  • [9] The Proteolytic Activity of Separase in BCR-ABL-Positive Cells Is Increased by Imatinib
    Haass, Wiltrud
    Stehle, Michael
    Nittka, Stefanie
    Giehl, Michelle
    Schrotz-King, Petra
    Fabarius, Alice
    Hofmann, Wolf-Karsten
    Seifarth, Wolfgang
    PLOS ONE, 2012, 7 (08):
  • [10] ABL-BCR expression in BCR-ABL-positive human leukemia cell lines
    Uphoff, CC
    Habig, S
    Fombonne, S
    Matsuo, Y
    Drexler, HG
    LEUKEMIA RESEARCH, 1999, 23 (11) : 1055 - 1060